Increased atherosclerotic lesion formation and vascular leukocyte accumulation in renal impairment are mediated by interleukin-17A

Circulation Research

Volumn 113, Issue 8, 2013, Pages 965-974

  Ge, Shuwang ^a,c   Hertel, Barbara ^a   Koltsova, Ekaterina K ^b   Sörensen Zender, Inga ^a   Kielstein, Jan T ^a   Ley, Klaus ^b   Haller, Hermann ^a   Von Vietinghoff, Sibylle ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Atherosclerosis; Interleukin 17; Leukocytes; Renal insufficiency; Vascular inflammation

Indexed keywords

APOLIPOPROTEIN E; GLYCOPROTEIN P 15095; HLA ANTIGEN CLASS 2; INTERLEUKIN 17; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE MARROW CELL; CELL CULTURE; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNINEPHRECTOMY; VASCULITIS;

ATHEROSCLEROSIS; INTERLEUKIN-17; LEUKOCYTES; RENAL INSUFFICIENCY; VASCULAR INFLAMMATION;

ANIMALS; ANTIGENS, CD11C; AORTA; AORTITIS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-17; KIDNEY; KIDNEY DISEASES; LEUKOCYTES; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; T-LYMPHOCYTES;

EID: 84885314476     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.301934     Document Type: Article

References (60)

1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol. 2006;17:2034-2047
2. Astor BC, Hallan SI, Miller ER III, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167:1226-1234
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305
4. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572-586
5. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007;116:85-97
6. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: Clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163:399-406
7. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047
8. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol. 2003;14:2466-2474
9. Buzello M, Törnig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein e knockout mouse: A model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003;14:311-316
10. Suganuma E, Zuo Y, Ayabe N, Ma J, Babaev VR, Linton MF, Fazio S, Ichikawa I, Fogo AB, Kon V. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J Am Soc Nephrol. 2006;17:433-441
11. Buzello M, Haas CS, Hauptmann F, Gross ML, Faulhaber J, Schultze- Mosgau S, Ehmke H, Ritz E, Amann K. No aggravation of renal injury in apolipoprotein E knockout mice (ApoE(-/-)) after subtotal nephrectomy. Nephrol Dial Transplant. 2004;19:566-573
12. Bro S, Moeller F, Andersen CB, Olgaard K, Nielsen LB. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-Edeficient mice. J Am Soc Nephrol. 2004;15:1495-1503
13. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drüeke TB, Muntzel MS. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol. 2005;16:109-116
14. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1599-1605
15. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20:1453-1464
16. Westenfeld R, Schäfer C, Krüger T, Haarmann C, Schurgers LJ, Reutelingsperger C, Ivanovski O, Drueke T, Massy ZA, Ketteler M, Floege J, Jahnen-Dechent W. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009;20:1264-1274
17. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol. 2008;8:802-815
18. Hansson GK, Libby P. The immune response in atherosclerosis: A doubleedged sword. Nat Rev Immunol. 2006;6:508-519
19. Wu H, Gower RM, Wang H, Perrard XY, Ma R, Bullard DC, Burns AR, Paul A, Smith CW, Simon SI, Ballantyne CM. Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation. 2009;119:2708-2717
20. Zhu SN, Chen M, Jongstra-Bilen J, Cybulsky MI. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J Exp Med. 2009;206:2141-2149
21. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, Ginhoux F, Miller ER, Witztum JL, Chapman MJ, Lesnik P. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation. 2009;119:2367-2375
22. Packard RR, Maganto-García E, Gotsman I, Tabas I, Libby P, Lichtman AH. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res. 2008;103:965-973
23. Rekhter MD, Gordon D. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am J Pathol. 1995;147:668-677
24. Choi JH, Cheong C, Dandamudi DB, Park CG, Rodriguez A, Mehandru S, Velinzon K, Jung IH, Yoo JY, Oh GT, Steinman RM. Flt3 signalingdependent dendritic cells protect against atherosclerosis. Immunity. 2011;35:819-831
25. Bobryshev YV. Dendritic cells in atherosclerosis: Current status of the problem and clinical relevance. Eur Heart J. 2005;26:1700-1704
26. Wick G, Romen M, Amberger A, Metzler B, Mayr M, Falkensammer G, Xu Q. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J. 1997;11:1199-1207
27. Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, Scott SR, von Vietinghoff S, Galkina E, Miller YI, Acton ST, Ley K. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest. 2012;122:3114-3126
28. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969-979
29. von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev. 2010;21:463-469
30. Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Böckler D, Katus HA, Dengler TJ. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009;183:8167-8175
31. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010;121:1746-1755
32. van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, Michon IM, de Vos P, van Berkel TJ, Kuiper J. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun. 2009;388:261-265
33. Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection- accelerated atherosclerosis in mice. J Immunol. 2010;185:5619-5627
34. Butcher MJ, Gjurich BN, Phillips T, Galkina EV. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res. 2012;110:675-687
35. Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, Iwakura Y, Blinder Y, Rahman A, Quyyumi AA, Harrison DG. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein edeficient mice. Arterioscler Thromb Vasc Biol. 2011;31:1565-1572
36. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, Mallat Z. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009;206:2067-2077
37. Cheng X, Taleb S, Wang J, et al. Inhibition of IL-17A in atherosclerosis. Atherosclerosis. 2011;215:471-474
38. Danzaki K, Matsui Y, Ikesue M, Ohta D, Ito K, Kanayama M, Kurotaki D, Morimoto J, Iwakura Y, Yagita H, Tsutsui H, Uede T. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32:273-280
39. von Vietinghoff S, Koltsova EK, Mestas J, Diehl CJ, Witztum JL, Ley K. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol. 2011;57:2194-2204
40. Koltsova EK, Kim G, Lloyd KM, Saris CJ, von Vietinghoff S, Kronenberg M, Ley K. Interleukin-27 receptor limits atherosclerosis in Ldlr-/- mice. Circ Res. 2012;111:1274-1285
41. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol. 2006;17:S169-S173
42. Chung BH, Kim KW, Sun IO, Choi SR, Park HS, Jeon EJ, Kim BM, Choi BS, Park CW, Kim YS, Cho ML, Yang CW. Increased interleukin-17 producing effector memory T cells in the end-stage renal disease patients. Immunol Lett. 2012;141:181-189. 974 Circulation Research September 27, 2013
43. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013;9:255-265
44. Hesselink DA, Betjes MG, Verkade MA, Athanassopoulos P, Baan CC, Weimar W. The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrol Dial Transplant. 2005;20:1868-1873
45. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science. 2013;339:166-172
46. von Vietinghoff S, Asagiri M, Azar D, Hoffmann A, Ley K. Defective regulation of CXCR2 facilitates neutrophil release from bone marrow causing spontaneous inflammation in severely NF-kappa B-deficient mice. J Immunol. 2010;185:670-678
47. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science. 2002;296:1869-1873
48. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin- 17 family members. Immunity. 2011;34:149-162
49. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-507
50. Liang J, Zheng Z, Wang M, Han L, Zheng Z, Peng J, Liu Z, Wei Y. Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes. J Int Med Res. 2009;37:862-866.
51. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460
52. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A. 2009;106:14948-14953
53. Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. Role of the reninangiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A. 2009;106:14942-14947
54. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S12-S154
55. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869
56. Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006;70:371-376
57. Barin JG, Baldeviano GC, Talor MV, Wu L, Ong S, Quader F, Chen P, Zheng D, Caturegli P, Rose NR, Ciháková D. Macrophages participate in IL-17-mediated inflammation. Eur J Immunol. 2012;42:726-736
58. Zuo Y, Yancey P, Castro I, Khan WN, Khan W, Motojima M, Ichikawa I, Fogo AB, Linton MF, Fazio S, Kon V. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol. 2009;29:1277-1282
59. Westerterp M, Murphy AJ, Wang M, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res. 2013;112:1456-1465
60. Chen X, Lu H, Rateri DL, Cassis LA, Daugherty A. Conundrum of angiotensin II and TGF- interactions in aortic aneurysms. Curr Opin Pharmacol. 2013;13:180-185